{"id":"NCT00513370","sponsor":"Abbott","briefTitle":"A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis","officialTitle":"A Canadian Open-Label Access Program to Evaluate the Safety and the Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2008-09","completion":null,"firstPosted":"2007-08-08","resultsPosted":"2009-11-20","lastUpdate":"2011-04-11"},"enrollment":203,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"Humira (adalimumab)","otherNames":["ABT-D2E7","adalimumab","Humira"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety profile, the effectiveness and the economic impact of adalimumab when used for the treatment of subjects with active plaque psoriasis who have not adequately responded to prior psoriasis therapy.","primaryOutcome":{"measure":"Number of Subjects With Psoriasis Area and Severity Index (PASI) 75 Response at 16 Weeks","timeFrame":"16 weeks","effectByArm":[{"arm":"Adalimumab 40 mg Eow - 16 Weeks","deltaMin":144,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":21},"locations":{"siteCount":27,"countries":["Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Influenza","Headache","Arthralgia"]}}